Fixed and random effects estimates were calculated and compared.52 Two meta-analyses of the incidence of EGFR-targeted agent associated rash were performed, one including and one excluding the study of minocycline in patients with mCRC treated with cetuximab.43 This was because the relative risk for this study43 was based on the presence of rash rather than the incidence of moderate/severe rash. The gene discussed is EGFR; the disease is exanthem.